L-778123

• Description :

  L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Farnesyl Transferase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/l-778123.html

• Purity :

  99.92

• Solubility :

  1 M HCl : ≥ 100 mg/mL|DMSO : 20 mg/mL (ultrasonic; adjust pH to 2 with 1 M HCl)

• Smiles :

  N#CC1=CC=C(CN2C(CN3CC(N(C4=CC=CC(Cl)=C4)CC3)=O)=CN=C2)C=C1

• Molecular Formula :

  C22H20ClN5O

• Molecular Weight :

  405.88

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lobell RB, et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther. 2002 Jul;1 (9) :747-758.|[2]Ghasemi S, et al. Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines. Adv Pharm Bull. 2013;3 (1) :73-77.|[3]Fredrick O. Onono, et al. The Farnesyltransferase Inhibitor (FTI) L-778,123 Displays Promising Anti-Leukemia Activity. Blood (2008) ; 112 (11) : 2627.|[4]Si MS, et al. Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123. Invest New Drugs. 2005 Jan;23 (1) :21-9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  ACS Nano. 2025 Aug 12;19 (31) :28644-28659.|bioRxiv. 2025 Jul 29.|bioRxiv. 2023 Feb 8:2023.02.07.527548.|Cell. 2025 Nov 24:S0092-8674 (25) 01244-9.|Immunity. 2024 May 14;57 (5) :1056-1070.e5.

• CAS Number :

  [183499-57-2]